oncology-therpeutics-2017-scientifictracks

Page 22

Notes:

allied

academies

J Med Oncl Ther 2017 Volume 2 | Issue 3

International Conference on

Oncology and Cancer Therapeutics

October 30- November 01, 2017 | Chicago, USA

Recent advancements in cancer genomics

Shrikant M Mane

Yale Center for Genome Analysis, USA

he Yale Center for Genome Analysis (YCGA) is a state-

of-the-art DNA Sequencing Center launched in 2010

to provide an open access centralized facility for services,

equipment and expertise required for carrying out large-

scale sequence analysis studies. Our group foresaw scientific

opportunities for the development and use of exome

sequencing in Mendelian genetics and was the first to

develop the method for exome capture on the NimbleGen/

Roche platform. We were also the first to demonstrate the

biological utility of exome sequencing for clinical diagnostic

applications. Currently, YCGA is a part of the NHGRI supported

Yale Center for Mendelian Genomics that uses NGS and

computational approaches to discover the genes and variants

that underlie Mendelian conditions. In the last four years,

the use of next-gen sequencing has led to the publications of

>375 articles in peer reviewed journals, including >40 in high

profile journals such as Science, Nature, Cell, New England

Journal of Medicine and Nature Genetics reporting new

variants in various disorders, including cancer, hypertension,

autism, several types of cancers, Gaucher disease, skin

disorders, and cortical malfunctions, all using exome analysis.

The presentation will focus on recent biomarker discoveries

in cancer and clinical applications.